NEOS Investment Management LLC Decreases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

NEOS Investment Management LLC lowered its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 23.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,261 shares of the biopharmaceutical company’s stock after selling 6,331 shares during the period. NEOS Investment Management LLC’s holdings in Celldex Therapeutics were worth $512,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in shares of Celldex Therapeutics by 103.3% during the fourth quarter. JPMorgan Chase & Co. now owns 85,545 shares of the biopharmaceutical company’s stock worth $2,162,000 after purchasing an additional 43,470 shares during the period. Vanguard Group Inc. lifted its holdings in Celldex Therapeutics by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock worth $98,098,000 after buying an additional 12,213 shares during the period. Fox Run Management L.L.C. grew its position in shares of Celldex Therapeutics by 149.8% in the 4th quarter. Fox Run Management L.L.C. now owns 23,290 shares of the biopharmaceutical company’s stock worth $589,000 after buying an additional 13,966 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Celldex Therapeutics during the fourth quarter valued at approximately $306,000. Finally, American Century Companies Inc. raised its holdings in shares of Celldex Therapeutics by 46.5% during the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company’s stock valued at $15,376,000 after acquiring an additional 193,093 shares in the last quarter.

Celldex Therapeutics Price Performance

CLDX opened at $19.93 on Monday. Celldex Therapeutics, Inc. has a 1 year low of $18.61 and a 1 year high of $47.00. The stock has a 50-day moving average price of $21.90 and a 200-day moving average price of $26.23. The firm has a market cap of $1.32 billion, a PE ratio of -7.75 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on CLDX shares. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group started coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 price target for the company. The Goldman Sachs Group cut their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, Morgan Stanley assumed coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They issued an “overweight” rating and a $46.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.33.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.